Yan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yan Zhang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Dandan Luo
1 shared publicationJinni Yang
Shandong University of Traditional Chinese Medicine, Jinan, 250355, Shandong Province, PR China
1 shared publicationLeilei Liu
Shandong University of Traditional Chinese Medicine, Jinan, 250355, Shandong Province, PR China
1 shared publication- Leilei Liu
College of traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250300, China
1 shared publication Shujun Wang
Shandong University of Traditional Chinese Medicine, Jinan, 250355, Shandong Province, PR China
1 shared publicationShuzhi Liang
Shandong University of Traditional Chinese Medicine, Jinan, 250355, Shandong Province, PR China
1 shared publication
Latest Publications
- Open Access
- 1 December 2025
- Published by KEAI Publishing in Journal of Holistic Integrative Pharmacy
- Vol. 6 (4) , 373-388
Banxia Shumi decoction targets ribosome biogenesis to alleviate insomnia
- 1 December 2025
- Published by KEAI Publishing in Journal of Holistic Integrative Pharmacy
- Vol. 6 (4) , 373-388
Open AccessBanxia Shumi decoction targets ribosome biogenesis to alleviate insomnia
- Open Access
Research Progress on the Mechanisms of Protocatechuic Acid in the Treatment of Cognitive Impairment
Cognitive impairment (CI) is a type of mental health disorder that mainly affects cognitive abilities, such as learning, memory, perception, and problem-solving. Currently, in clinical practice, the treatment of cognitive impairment mainly focuses on the application of cholinesterase inhibitors and NMDA receptor antagonists; however, there is no specific and effective drug yet. Procatechuic acid (PCA) possesses various functions, including antibacterial, antiasthmatic, and expectorant effects. In recent years, it has received growing attention in the cognitive domain. Therefore, by summarizing the mechanisms of action of procatechuic acid in the treatment of cognitive impairment in this paper, it is found that procatechuic acid has multiple effects, such as regulating the expression of neuroprotective factors, inhibiting cell apoptosis, promoting the autophagy-lysosome pathway, suppressing oxidative stress damage, inhibiting inflammatory responses, improving synaptic plasticity dysfunction, inhibiting Aβ deposition, reducing APP hydrolysis, enhancing the cholinergic system, and inhibiting the excitotoxicity of neuronal cells. The involved signaling pathways include activating Pi3K-akt-mTor and inhibiting JNK, P38 MAPK, P38-ERK-JNK, SIRT1, and NF-κB/p53, etc. This paper aims to present the latest progress in research on procatechuic acid, including aspects such as its chemical properties, sources, pharmacokinetics, mechanisms for treating neurodegenerative diseases.
Open AccessResearch Progress on the Mechanisms of Protocatechuic Acid in the Treatment of Cognitive Impairment
Cognitive impairment (CI) is a type of mental health disorder that mainly affects cognitive abilities, such as learning, memory, perception, and problem-solving. Currently, in clinical practice, the treatment of cognitive impairment mainly focuses on the application of cholinesterase inhibitors and NMDA receptor antagonists; however, there is no specific and effective drug yet. Procatechuic acid (PCA) possesses various functions, including antibacterial, antiasthmatic, and expectorant effects. In recent years, it has received growing attention in the cognitive domain. Therefore, by summarizing the mechanisms of action of procatechuic acid in the treatment of cognitive impairment in this paper, it is found that procatechuic acid has multiple effects, such as regulating the expression of neuroprotective factors, inhibiting cell apoptosis, promoting the autophagy-lysosome pathway, suppressing oxidative stress damage, inhibiting inflammatory responses, improving synaptic plasticity dysfunction, inhibiting Aβ deposition, reducing APP hydrolysis, enhancing the cholinergic system, and inhibiting the excitotoxicity of neuronal cells. The involved signaling pathways include activating Pi3K-akt-mTor and inhibiting JNK, P38 MAPK, P38-ERK-JNK, SIRT1, and NF-κB/p53, etc. This paper aims to present the latest progress in research on procatechuic acid, including aspects such as its chemical properties, sources, pharmacokinetics, mechanisms for treating neurodegenerative diseases.
- 29 July 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 318 (Pt B) , 116973
Effects of BXSMD on ESR1 and ESR2 expression in CSD female mice
- 29 July 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 318 (Pt B) , 116973
Effects of BXSMD on ESR1 and ESR2 expression in CSD female mice